Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

• Main Authors: Saul N. Faust (Author), Maguelone Le Roy (Author), Chitsanu Pancharoen (Author), Miguel Angel Rodriguez Weber (Author), Katrina Cathie (Author), Ulrich Behre (Author), Jolanta Bernatoniene (Author), Matthew D. Snape (Author), Klaus Helm (Author), Carlos Eduardo Medina Pech (Author), Ouzama Henry (Author), Carmen Baccarini (Author), Michael Povey (Author), Paul Gillard (Author)
• Formato: Libro
• Publicado: BMC, 2019-02-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract Background A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to t...